6 Hrs
Source:
المشهد
FDA May Reject Lung Drug
The U.S. Food and Drug Administration declined to approve Summit Therapeutics’ ivonescimab for lung cancer, even though trials showed a notable delay in disease progression, because the drug had not demonstrated a statistically significant improvement in overall survival. In support of its application, the company submitted updated follow-up data indicating sustained benefit and a reduced risk of death among subgroups of Asian and Western patients.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)